Botulinum neurotoxin intramuscular chemodenervation: Role in the management of spastic hypertonia and related motor disorders

Physical Medicine and Rehabilitation Clinics of North America

Volumn 12, Issue 4, 2001, Pages 833-874

  Yablon, S A ^a  

^a METHODIST REHABILITATION CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BOTULINUM TOXIN; BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ADULT; ANATOMY; BRAIN INJURY; CENTRAL NERVOUS SYSTEM DISEASE; CEREBRAL PALSY; CHILD; CLINICAL TRIAL; DISEASE SEVERITY; DOSE CALCULATION; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG SAFETY; FEMALE; HUMAN; MALE; MOTOR DYSFUNCTION; MULTIPLE SCLEROSIS; MUSCLE DENERVATION; MUSCLE HYPERTONIA; MUSCLE WEAKNESS; NERVOUS SYSTEM INJURY; PATIENT SELECTION; PRIORITY JOURNAL; RESPIRATORY ARREST; REVIEW; SPASTICITY; STROKE; TECHNIQUE;

EID: 0035155788     PISSN: 10479651     EISSN: None     Source Type: Journal    
DOI: 10.1016/s1047-9651(18)30035-4     Document Type: Review

References (146)

1. The role of electromyography in guiding botulinum toxin injections for focal dystonia and spasticity
2. Has botulinum toxin type A a place in the treatment of spinal cord injury patients?
3. Physical and occupational therapy considerations in adult patients receiving botulinum toxin injections for spasticity
4. Continuous intrathecal baclofen infusion for spasticity of cerebral origin
5. Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders
6. Preclinical update on BOTOX® (botulinum toxin type A)-purified neurotoxin complex relative to other botulinum neurotoxin preparations
7. Botulinum toxin A in the hemiplegic upper limb: A double blind trial
8. Botulinum toxin injection as an adjunct when planning hand surgery in children with spastic hemiplegia
9. A randomized, double-blind, placebo-controlled, dose-ranging study to compare the efficacy and safety of three doses of botulinum toxin type A (Dysport) with placebo in upper limb spasticity after stroke
10. Generalised botulism-like syndrome after intramuscular injections of botulinum toxin type A: A report of two cases
11. Botulinum toxin type A in the treatment of upper limb spasticity
12. Continuous intrathecal baclofen infusion in severe spasticity after traumatic or hypoxic brain injury
13. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: A randomized double blind placebo controlled trial
14. Use of botulinum toxin in stroke patients with severe upper limb spasticity
15. Flexor digitorum superficialis: Locations of individual muscle bellies for botulinum toxin injections
16. Treatment of spastic hypertonia in brain injured patients with botulinum A toxin
17. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25
18. Interrater reliability of a modified Ashworth scale of muscle spasticity
19. Botulinum toxin for the treatment of spasticity in multiple sclerosis
20. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injections
21. Transient urinary incontinence after botulinum A toxin
22. BOTOX Post-Stroke Study Group: A multicenter, double-blind, randomized, placebo-controlled, parallel study of the safety and efficacy of BOTOX (Botulinum Toxin Type A) Purified Neurotoxin in the treatment of focal upper limb spasticity poststroke
23. Botulinum toxin: Chemistry, pharmacology, toxicity, and immunology
24. Dosing, administration, and a treatment algorithm for use of botulinum toxin A for adult-onset spasticity
25. A randomised, double-blind, placebo controlled trial of botulinum toxin in the treatment of spastic foot in hemiparetic patients
26. Electrophysiologic identification of motor points during injection of botulinum toxin: A pilot study
27. Position paper on the use of botulinum toxin in cerebral palsy
28. Effect of muscle activity immediately after botulinum toxin injection for writer's cramp
29. A multicenter, double-blind, placebo-controlled dose response trial of botulinum-toxin type A (Botox®) in upper limb spasticity post-stroke
30. Comparison of two injection techniques using botulinum toxin in spastic hemiplegia
31. Management of spasticity in children with botulinum-A toxin
32. Botulism-like syndrome after injections of botulinum toxin
33. Dysphagia after botulinum toxin injections for spasmodic torticollis. Clinical and radiologic findings
34. Botulinum toxin A compared with stretching casts in the treatment of spastic equines: A randomized prospective trial
35. Botulinum toxin A in hamstring spasticity
36. Botulinum toxin A in the hemiplegic upper limb: A double-blind trial
37. Botulinum toxin in the management of the lower limb in cerebral palsy
38. Botulinum toxin A prevents the development of contractures in the hereditary spastic mouse
39. Botulinum toxin in treating spasticity
40. Effect of treatment with botulinum toxin on spasticity
41. Botulinum toxin and spasticity
42. Functional repair of motor endplates after botulinum neurotoxin type A poisoning: Biphasic switch of synaptic activity between nerve sprouts and their parent terminals
43. Local botulinum toxin in the treatment of spastic drop foot
44. Botulinum toxin in the treatment of cerebral palsy
45. Treatment of chronic limb spasticity with botulinum toxin A
46. Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: A double-blind study
47. Botulinum toxin treatment in the facial muscles of humans: Evidence of an action in untreated near muscles by peripheral local diffusion
48. An evaluation of botulinum-A toxin injections to improve upper extremity function in children with hemiplegic cerebral palsy
49. Isokinetic dynamometric technique for spasticity assessment
50. Botulinum toxin A versus fixed cast stretching for dynamic calf tightness in cerebral palsy
51. Botulinum toxin treatment in cerebral palsy: Intervention with poor evaluation?
52. Botulinum toxin treatment of upper extremity spasticity: A comparison of two commonly used dilution techniques
53. Effects of botulinum toxin A on upper limb spasticity in children with cerebral palsy
54. Localizing muscles for botulinum toxin treatment of focal hand dystonia
55. Effects of botulinum toxin type A on intracortical inhibition in patients with dystonia
56. Intrathecal baclofen for management of spastic cerebral palsy: Multicenter trial
57. Botulinum toxin therapy: Distant effects on neuromuscular transmission and autonomic nervous system
58. Chemical denervation for the treatment of hypertonia and related motor disorders: Phenol and botulinum toxin
59. Botulinum toxin for spasticity and athetosis in children with cerebral palsy
60. Use of botulinum toxin type A in pediatric patients with cerebral palsy: A three-center retrospective chart review
61. A clinical overview of treatment decisions in the management of spasticity
62. Traditional pharmacological treatments for spasticity part I: Local treatments
63. Traditional pharmacological treatments for spasticity part II: General and regional treatments
64. Evidence for increased antagonist strength and movement speed following botulinum toxin injections in spasticity
65. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy
66. Botulinum toxin A for spasticity, muscle spasms, and rigidity
67. The changing face of cerebral palsy: A review of the disorder and its treatment
68. Development of resistance to botulinum toxin type A in patients with torticollis
69. How does botulinum toxin work?
70. Serial neurophysiological studies of intramuscular botulinum-A toxin in humans
71. Botulinum toxin therapy for upper limb flexor spasticity: Preliminary results
72. Short-term electrical stimulation enhances the effectiveness of botulinum toxin in the treatment of lower limb spasticity in hemiparetic patients
73. Botulinum toxin treatment for lower limb extensor spasticity in chronic hemiparetic patients
74. Botulinum toxin type A and short term electrical stimulation in the treatment of upper limb flexor spasticity after stroke: A randomised, double blind, placebo controlled trial
75. Complications among patients receiving botulinum toxin A injection for spastic hypertonia
76. Influence of nerve-ending activity and of drugs on the rate of paralysis of rate diaphragm preparation by Clostridium botulinum type toxin A
77. Botulinum toxin (Dysport®) treatment of hip adductor spasticity in multiple sclerosis: A prospective, randomised, double blind, placebo controlled, dose ranging study
78. Spastic hypertonia: Mechanisms and measurement
79. Dynamic electromyography to assess elbow spasticity
80. Comparison of phenol block and botulinus toxin type A in the treatment of spastic foot after stroke. A randomized, double-blind trial
81. Management of cerebral palsy with botulinum-A toxin: Preliminary investigation
82. Management of spasticity in cerebral palsy with botulinum-A toxin: Report of a preliminary, randomized, double-blind trial
83. Botulinum toxin type A neuromuscular blockade in the treatment of lower extremity spasticity in cerebral palsy: A randomized, double-blind, placebo-controlled trial
84. Post-stroke spasticity management with repeated botulinum toxin injections in the upper limb
85. Symposium synopsis
86. Evaluation of botulinum toxin A therapy in children with adductor spasm by gross motor function measure
87. Botulism
88. Role of exercise testing in the functional assessment of cerebral palsy children after botulinum toxin injection
89. Clinicophysiologic concepts of spasticity and motor dysfunction in adults with an upper motoneuron lesion
90. Common patterns of clinical motor dysfunction
91. Traitement de la spasticité par la toxine botulique
92. Treatment of dysfunctional focal spastic hypertonia among patients with spinal cord injury: The role of botulinum toxin A in eight patients
93. Prospective assessment of continuous intrathecal infusion of baclofen for spasticity caused by acquired brain injury: A preliminary report
94. Double-blind cross-over titration on the safety and efficacy of tizanidine for spastic hypertonia due to acquired brain injury
95. Injection techniques for botulinum toxin using electromyography and electrical stimulation
96. Botulinum toxin treatment of lumbrical spasticity: A brief report
97. Functional and clinical changes in upper limb spastic patients treated with botulinum toxin (BTX)
98. Botulinum toxin type-A treatment in spastic paraparesis: A neurophysiological study
99. Botulinum toxin type A in the treatment of upper limb spasticity among patients with traumatic brain injury
100. Intrathecal baclofen for spinal spasticity
101. Botulinum toxin A in the treatment of spasticity: Functional implications and treatment selection
102. Physiological effects produced by botulinum toxin treatment of upper limb dystonia: Changes in reciprocal inhibition between forearm muscles
103. Disability changes after treatment of upper limb spasticity with botulinum toxin
104. Low-dose botulinum toxin with ankle taping for the treatment of spastic equinovarus foot after stroke
105. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults
106. The type A botulinum toxin in the treatment of spasticity in evolutive age
107. Safety of "high dose" botulinum toxin A injection for spasticity in adults
108. Suboptimal response of index distal phalanx spasticity following treatment with botulinum toxin A: Indications for precise muscle localization with needle stimulation
109. Extrafusal and intrafusal muscle effects in experimental botulinum toxin-A injection
110. Botulinum toxin in cerebral palsy: Experiences from an open study
111. Cerebral palsy: A rational approach to a treatment protocol, and the role of botulinum toxin in treatment
112. Botulinum toxin type A for the treatment of arm and hand spasticity in stroke patients
113. Properties and use of botulinum toxin and other microbial neurotoxins in medicine
114. High-dose tizanidine treatment produces minor cardiovascular and hepatic effects: An open-label study of 176 patients with spasticity from multiple sclerosis or spinal cord injury
115. Tetanus and botulinum B neurotoxins block neurotransmitter release by proteolytic cleavage of synaptobrevin
116. Identification of the nerve terminal targets of botulinum neurotoxin serotypes A, D, and E
117. Botulinum neurotoxins serotypes A and E cleave SNAP-25 at distinct COOH-terminal peptide bonds
118. An update on the treatment of detrusor-sphincter dyssynergia with botulinum toxin type A
119. The biochemistry of botulinum toxin type B
120. Quantifying how location and dose of botulinum toxin injections affect muscle paralysis
121. Treatment of spasticity with botulinum toxin
122. Botulinum toxin type A in the treatment of upper extremity spasticity: A randomized, double-blind, placebo-controlled trial
123. Muscle paralysis produced by botulinum toxin type A injection in treated torticollis patients compared with toxin naive individuals
124. Dose-response curve of human extensor digitorum brevis muscle function to intramuscularly injected botulinum toxin type A
125. A double-blind placebo-controlled study of botulinum toxin in upper limb spasticity after stroke or head injury
126. Treatment of spasticity with botulinum toxin: A double-blind study
127. SNAP receptors implicated in vesicle targeting and fusion
128. Managing spasticity in pediatric cerebral palsy using a very low dose of botulinum toxin type A: Preliminary report
129. Double-blind study of botulinum A toxin injections into the gastrocnemius muscle in patients with cerebral palsy
130. Injection of botulinum A toxin into the gastrocnemius muscle of patients with cerebral palsy: A 3-dimensional motion analysis study
131. À la d'une techique de mesure de la spasticité
132. Randomised double blind placebo controlled trial of the effect of botulinum toxin on walking in cerebral palsy
133. 125-I-labeled botulinum A neurotoxin: Pharmacokinetics in cats after intramuscular injection
134. Kinematic changes following botulinum toxin injection after traumatic brain injury
135. Ground reaction force changes in hemiparetic gait following botulinum toxin injection
136. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy: A randomized, double-blind study of "high-dose" versus "low-dose" treatment
137. Gait analysis to assess the effects of botulinum toxin type A treatment in cerebral palsy: An open label study in 10 children with equines gait pattern
138. Management of spasticity associated pain with botulinum toxin A
139. Use of botulinum toxin injection in 17 children with spastic cerebral palsy
140. Botulinum toxin in severe upper extremity spasticity among patients with traumatic brain injury: An open-labeled trial